OneDigital Investment Advisors LLC Sells 853 Shares of Eli Lilly and Company $LLY

OneDigital Investment Advisors LLC lessened its position in shares of Eli Lilly and Company (NYSE:LLY) by 7.1% during the 3rd quarter, Holdings Channel.com reports. The firm owned 11,145 shares of the company’s stock after selling 853 shares during the quarter. OneDigital Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $8,504,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the company. Princeton Capital Management LLC lifted its position in Eli Lilly and Company by 7.9% in the third quarter. Princeton Capital Management LLC now owns 16,350 shares of the company’s stock worth $12,475,000 after purchasing an additional 1,202 shares during the period. Journey Advisory Group LLC raised its stake in shares of Eli Lilly and Company by 1.0% in the 3rd quarter. Journey Advisory Group LLC now owns 23,152 shares of the company’s stock valued at $17,665,000 after buying an additional 234 shares in the last quarter. Rossby Financial LCC lifted its holdings in shares of Eli Lilly and Company by 23.0% during the 3rd quarter. Rossby Financial LCC now owns 1,523 shares of the company’s stock worth $1,257,000 after acquiring an additional 285 shares during the period. Jackson Grant Investment Advisers Inc. boosted its position in shares of Eli Lilly and Company by 0.9% during the 3rd quarter. Jackson Grant Investment Advisers Inc. now owns 2,811 shares of the company’s stock valued at $2,145,000 after acquiring an additional 24 shares in the last quarter. Finally, Siligmueller & Norvid Wealth Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at about $229,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have commented on LLY. Berenberg Bank raised their price target on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a research note on Thursday. UBS Group reissued a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 2nd. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 31st. Barclays started coverage on Eli Lilly and Company in a research note on Thursday. They issued an “overweight” rating and a $1,350.00 price target on the stock. Finally, Loop Capital set a $1,200.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, February 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $1,228.54.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,008.47 on Monday. The stock has a 50-day simple moving average of $1,054.83 and a 200 day simple moving average of $917.84. The stock has a market capitalization of $951.35 billion, a price-to-earnings ratio of 43.94, a P/E/G ratio of 1.17 and a beta of 0.39. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter last year, the company posted $5.32 EPS. The company’s quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is presently 30.15%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Landmark long‑term Omvoh (mirikizumab) data — Phase 3 VIVID‑2 open‑label results showed >90% of Crohn’s patients who reached steroid‑free remission at one year remained steroid‑free at three years; low hospitalization and surgery rates reinforce Omvoh’s potential to reduce disease complications and extend market opportunity in IBD. Patients with Crohn’s disease maintained steroid-free remission for three years with Lilly’s Omvoh
• Positive Sentiment: Additional trial wins — Lilly reported another positive result for the Zepbound‑Taltz combination (psoriasis/obesity crossover strategy) and other pipeline progress that support revenue diversification beyond GLP‑1s. These clinical wins strengthen near‑ and medium‑term growth expectations. Lilly chalks up another trial win for Zepbound‑Taltz combo
• Positive Sentiment: Analyst support — Berenberg raised its price target from $950 to $1,050 while keeping a hold rating, signaling modest upside in analyst models that may buoy sentiment after recent gains. Berenberg adjusts price target on Eli Lilly
• Neutral Sentiment: Business development — Lilly entered a $100M licensing deal with CSL for clazakizumab, which diversifies partnerships and could add mid‑late‑stage value but is not immediately material to top‑line. Eli Lilly Enters $100 Million Licensing Agreement with CSL Limited
• Neutral Sentiment: New indications / trials — Lilly has launched/updated trials (e.g., brenipatide Phase 2 for opioid use disorder) that expand the pipeline but are early‑stage and carry typical clinical risk/reward. Eli Lilly pushes into opioid use disorder with new brenipatide Phase 2 trial
• Negative Sentiment: Valuation and GLP‑1 concentration risk — Commentary and analysis pieces flag that much of Lilly’s recent rally was driven by GLP‑1/weight‑loss momentum; competition and profitability normalization risks remain, which can prompt profit‑taking and cap further near‑term gains. Warning: This Skyrocketing Stock Has a Hidden Risk

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.